Biofil Chemicals

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE829A01014
  • NSEID: BIOFILCHEM
  • BSEID: 524396
INR
30.72
1.01 (3.4%)
BSENSE

Nov 20

BSE+NSE Vol: 28.28 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 386748,
    "name": "Biofil Chemicals",
    "stock_name": "Biofil Chemicals",
    "full_name": "Biofil Chemicals & Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/biofil-chemicals",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "30.72",
    "chg": 1.01,
    "chgp": "3.4%",
    "dir": 1,
    "prev_price": "29.71",
    "mcapval": "50.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524396,
    "symbol": "BIOFILCHEM",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE829A01014",
    "curr_date": "Nov 20",
    "curr_time": "",
    "bse_nse_vol": "28.28 k",
    "exc_status": "Active",
    "traded_date": "Nov 20, 2026",
    "traded_date_str": "2026 11 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/biofil-chemicals-386748-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Biofil Chemicals & Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/biofil-chemicals-pharmaceuticals-ltd-is-rated-strong-sell-4242014",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/BiofilChemicals_mojoScore_4242014.png",
        "date": "2026-10-28 10:10:25",
        "description": "Biofil Chemicals & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 16 September 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 28 October 2026, providing investors with the latest perspective on the company’s position."
      },
      {
        "title": "Biofil Chemicals & Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/biofil-chemicals-pharmaceuticals-ltd-is-rated-strong-sell-4227788",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/BiofilChemicals_mojoScore_4227788.png",
        "date": "2026-10-16 10:10:25",
        "description": "Biofil Chemicals & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 16 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 October 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Biofil Chemicals & Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/biofil-chemicals-pharmaceuticals-ltd-is-rated-strong-sell-4208507",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/BiofilChemicals_mojoScore_4208507.png",
        "date": "2026-09-29 10:10:18",
        "description": "Biofil Chemicals & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 16 September 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 29 September 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Biofil Chemicals & Pharmaceuticals Ltd Downgraded to Sell Amid Mixed Technicals and Weak Fundamentals",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/biofil-chemicals-pharmaceuticals-ltd-downgraded-to-sell-amid-mixed-technicals-and-weak-fundamentals-4192283",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/BiofilChemicals_mojoScore_4192283.png",
        "date": "2026-09-14 08:08:33",
        "description": "Biofil Chemicals & Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 11 Sep 2026, driven primarily by a shift in technical indicators despite persistent fundamental weaknesses. The micro-cap pharmaceutical company’s Mojo Score improved to 37.0, reflecting a more optimistic technical outlook, even as valuation and financial trends remain challenging."
      },
      {
        "title": "Biofil Chemicals & Pharmaceuticals Ltd Locks at Upper Circuit With 19.58% Gain — Buyers Queue, Sellers Absent",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/biofil-chemicals-pharmaceuticals-ltd-surges-to-upper-circuit-on-robust-buying-pressure-4189562",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/BiofilChemicals_stocks_hitting_upper_circuit_4189562.png",
        "date": "2026-09-10 14:00:10",
        "description": "At Rs 37.75, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Biofil Chemicals & Pharmaceuticals Ltd locked at its upper circuit of 19.58% on 10 Sep 2026, with buyers queuing and no sellers willing to part with shares."
      }
    ],
    "total": 38,
    "sid": "386748",
    "stock_news_url": "https://researchintel.adityabirlamoney.com/news/biofil-chemicals-pharmaceuticals-386748"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "16-Nov-2026",
      "details": "Submission of publication of Un-audited financial results in the Newspaper pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.",
      "source": "BSE"
    },
    {
      "caption": " To Review Consider And Approve The Standalone Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September 2026 Along With Limited Review Report.",
      "datetime": "14-Nov-2026",
      "details": "To review consider and approve the Standalone Unaudited Financial Results for the quarter and half year ended on 30th September 2026 along with limited review report",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Board Meeting Outcome To Review Consider And Approve The Standalone Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September 2026 Along With Limited Review Report",
      "datetime": "14-Nov-2026",
      "details": "To review consider and approve the Standalone Unaudited Financial Results for the quarter and half year ended on 30th September 2026 along with Limited Review Report.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views
stock-recommendationAnnouncement

Announcement under Regulation 30 (LODR)-Newspaper Publication

16-Nov-2026 | Source : BSE

Submission of publication of Un-audited financial results in the Newspaper pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

To Review Consider And Approve The Standalone Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September 2026 Along With Limited Review Report.

14-Nov-2026 | Source : BSE

To review consider and approve the Standalone Unaudited Financial Results for the quarter and half year ended on 30th September 2026 along with limited review report

Board Meeting Outcome for Board Meeting Outcome To Review Consider And Approve The Standalone Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September 2026 Along With Limited Review Report

14-Nov-2026 | Source : BSE

To review consider and approve the Standalone Unaudited Financial Results for the quarter and half year ended on 30th September 2026 along with Limited Review Report.

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available